Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2251395 | 1.00 | NPC1 (0.40) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL2248688 | 1.00 | NPC1 (0.40) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL29388571 | 1.00 | NPC1 (0.40) | NPC1RAB9ATNFALOX15KDM4E | |
| Formic Acid SCHEMBL2252830 | 0.96 | NPC1 (0.37) | NPC1RAB9ATNFALOX15KDM4E | |
| Formic Acid SCHEMBL19630437 | 0.95 | NPC1 (0.37) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL20469302 | 0.89 | NPC1 (0.39) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL19603302 | 0.89 | ALOX15 (0.34) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL27432117 | 0.89 | NPC1 (0.39) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL27432120 | 0.89 | NPC1 (0.39) | NPC1RAB9ATNFALOX15KDM4E | |
| SCHEMBL7857212 | 0.89 | TNF (0.39) | NPC1RAB9ATNFALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4467143-B1 | METHOD FOR PREPARING 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024263781-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4467143-A2 | 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE AS ANTIPROLIFERATIVE COMPOUND | Celgene Corporation (US) | 2024-11-27 | — | — | EP | disclosed |
| EP-3651766-B1 | 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE AS ANTIPROLIFERATIVE COMPOUND | CELGENE CORP (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-112399848-B | Antiproliferative compounds and bispecific antibodies against BCMA and CD3 for combined use | 细胞基因公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20240041894-A1 | 3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | CELGENE CORPORATION | 2024-02-08 | — | — | US | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4221712-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | Celgene Corporation (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-110869021-B | Antiproliferative compounds and methods of use thereof | 细胞基因公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116234553-A | Methods of treating systemic lupus erythematosus and use of biomarkers as predictors of clinical sensitivity to therapy | 新基公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| CN-115068484-A | Treatment of immune-related and inflammatory diseases | 细胞基因公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114939119-A | Treatment of immune-related and inflammatory diseases | 细胞基因公司 | 2022-08-26 | — | — | CN | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| CN-111285850-B | Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| CN-114366746-A | Treatment of cancer using oxoisoindole compounds | 细胞基因公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114344307-A | Treatment of cancer using oxoisoindole compounds | 细胞基因公司 | 2022-04-15 | — | — | CN | disclosed |
| WO-2022072576-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | CELGENE CORPORATION (US) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041894-A1 | 3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, BCL6B, BCL6 | NPC1 1692/4885RAB9A 3672/4885TNF 2177/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | NPC1 91/4885RAB9A 3351/4885TNF 4590/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | NPC1 91/4885RAB9A 3351/4885TNF 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.